Prognostic Value Of Human Equilibrative Nucleoside Transporter 1 Levels In Patients With Pancreatic Cancer Receiving Gemcitabine Treatment

Objective:To explore the prognostic value of human equilibrative nucleoside transporter 1(hENT1)expression for the prognosis of patients with pancreatic cancer receiving gemcitabine treatment.Methods:Totally 30 clinical cases from December 2012 to September 2016 were retrospectively analyzed in the Sir Run Run Shaw Hospital of Zhejiang University School of Medicine.The Chi-square test was used to analyze the relationships between human equilibrative nucleoside transporter 1(hENT1)expression and clinical characteristics.Prognostic factors were studied by multivariate analyzed with Kaplan-Meier estimation and COX proportion hazards survival model.Results:In our study,no clinical indexes have relation with hENT1.Multivariable analysis confirmed hENT1 expression as a predictive marker in gemcitabine-treated(P=.047)patients.Conclusion:gemcitabine should not be used for patients with low tumor hENTl expression.